RA Capital Management 13F holdings, Q2 2014
Holdings as of June 30, 2014 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 24 US equity positions worth $756.1m in its Q2 2014 13F filing. The largest position was ACHILLION PHARMACEUTICALS INC at 22.5% of the reported book, followed by DYAX CORP and ENTA. Against the Q1 2014 filing, it opened 5 new positions, added to 2 and reduced 12 among the top 24 holdings.
What did RA Capital Management own in Q2 2014? Top 24 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2014 |
|---|---|---|---|---|---|---|---|
| 1 | ACHILLION PHARMACEUTICALS INC | 22.5% | $170.2m | 22,486,007 | -4% | reduced | |
| 2 | DYAX CORP | 12.7% | $95.8m | 9,982,578 | 34% | added | |
| 3 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 8.8% | $66.3m | 1,539,586 | -0% | held |
| 4 | DICERNA PHARMACEUTICALS INC | 7.2% | $54.8m | 2,428,571 | 0% | held | |
| 5 | VERSARTIS INC | 6.6% | $50.1m | 1,203,002 | – | new | |
| 6 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 5.6% | $42.6m | 2,791,305 | -47% | reduced |
| 7 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 5.4% | $40.8m | 3,198,529 | -26% | reduced |
| 8 | SUNESIS PHARMACEUTICALS INC | 4.2% | $31.7m | 4,869,261 | 0% | held | |
| 9 | NVAX NOVAVAX INC | Healthcare | 4.1% | $30.8m | 6,661,731 | -33% | reduced |
| 10 | DYNAVAX TECHNOLOGIES CORP | 3.0% | $22.5m | 14,036,590 | -22% | reduced | |
| 11 | OPHTHOTECH CORP | 3.0% | $22.3m | 527,941 | -70% | reduced | |
| 12 | REPROS THERAPEUTICS INC | 2.8% | $21.1m | 1,219,381 | -15% | reduced | |
| 13 | BLUEBIRD BIO INC | 2.6% | $19.4m | 503,062 | 8% | added | |
| 14 | TXMD THERAPEUTICSMD INC | 2.5% | $19.0m | 4,303,066 | -56% | reduced | |
| 15 | AKBA AKEBIA THERAPEUTICS INC | Healthcare | 2.2% | $16.6m | 597,363 | – | new |
| 16 | XNCR XENCOR INC | Healthcare | 1.6% | $11.8m | 1,016,735 | -63% | reduced |
| 17 | PSIVIDA CORP | 1.5% | $11.1m | 2,555,659 | 0% | held | |
| 18 | ARROWHEAD RESH CORP | 1.1% | $8.6m | 604,346 | -79% | reduced | |
| 19 | SCYX SCYNEXIS INC | 0.9% | $6.7m | 840,000 | – | new | |
| 20 | ALIMERA SCIENCES INC | 0.5% | $4.0m | 666,667 | 0% | held | |
| 21 | OCERA THERAPEUTICS INC | 0.5% | $3.7m | 490,697 | -7% | reduced | |
| 22 | IMMU IMMUNOMEDICS INC | 0.5% | $3.6m | 1,000,000 | – | new | |
| 23 | OXYGEN BIOTHERAPEUTICS INC | 0.2% | $1.3m | 315,298 | – | new | |
| 24 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 0.1% | $1.0m | 68,968 | -94% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.